Prospective Study of Small Cell Lung Cancer Patients Receiving Radiotherapy and Comprehensive Treatment to Personalize Care and Optimize Radio-Immunotherapy

What this Trial Is About

Researchers are creating a forward-looking clinical group of patients with small cell lung cancer SCLC to collect detailed real-world information from clinical exams, imaging, pathology, and molecular studies. This approach aims to support personalized treatment tailored to specific SCLC subtypes. The study also examines how the timing, dose, fractionation, and target areas of radiotherapy affect treatment results and side effects, with the goal of finding the best combination of radiotherapy and immunotherapy for SCLC patients. The study observes patients receiving radiotherapy combined with chemotherapy, with or without immunotherapy, as part of routine care. Different schedules for combining radiotherapy and immunotherapy, various radiation doses, fractionation plans, and target areas including prophylactic cranial irradiation PCI are used. Various immune checkpoint inhibitors are also employed. This observational design allows researchers to assess diverse treatment approaches within standard clinical practice. Participants will be monitored through assessments of progression-free survival and overall survival up to 12 months after enrollment ends. Additional outcomes tracked include distant metastasis-free survival, locoregional recurrence-free survival, objective response rate, disease control rate, and local control rate over the same period. Data collection includes clinical evaluations, imaging, and laboratory tests. This comprehensive monitoring helps evaluate treatment effectiveness and safety while supporting personalized care strategies for SCLC patients.

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment